These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19088049)

  • 1. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC.
    van Erp N; Gelderblom H; van Glabbeke M; Van Oosterom A; Verweij J; Guchelaar HJ; Debiec-Rychter M; Peng B; Blay JY; Judson I
    Clin Cancer Res; 2008 Dec; 14(24):8308-13. PubMed ID: 19088049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
    Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
    Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
    Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
    J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate.
    Smith P; Bullock JM; Booker BM; Haas CE; Berenson CS; Jusko WJ
    Pharmacotherapy; 2004 Nov; 24(11):1508-14. PubMed ID: 15537555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
    Soo GW; Law JH; Kan E; Tan SY; Lim WY; Chay G; Bukhari NI; Segarra I
    Anticancer Drugs; 2010 Aug; 21(7):695-703. PubMed ID: 20629201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
    Van Glabbeke M; Verweij J; Casali PG; Simes J; Le Cesne A; Reichardt P; Issels R; Judson IR; van Oosterom AT; Blay JY
    Eur J Cancer; 2006 Sep; 42(14):2277-85. PubMed ID: 16876399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
    Eechoute K; Fransson MN; Reyners AK; de Jong FA; Sparreboom A; van der Graaf WT; Friberg LE; Schiavon G; Wiemer EA; Verweij J; Loos WJ; Mathijssen RH; De Giorgi U
    Clin Cancer Res; 2012 Oct; 18(20):5780-7. PubMed ID: 22850565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group.
    Johansen M; Kuttesch J; Bleyer WA; Krailo M; Ames M; Madden T
    Clin Cancer Res; 2006 Jan; 12(2):516-22. PubMed ID: 16428494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
    Judson I; Ma P; Peng B; Verweij J; Racine A; di Paola ED; van Glabbeke M; Dimitrijevic S; Scurr M; Dumez H; van Oosterom A
    Cancer Chemother Pharmacol; 2005 Apr; 55(4):379-386. PubMed ID: 15592836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Cohen MH; Farrell A; Justice R; Pazdur R
    Oncologist; 2009 Feb; 14(2):174-80. PubMed ID: 19193781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)].
    Delbaldo C
    Therapie; 2007; 62(2):87-90. PubMed ID: 17582306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine.
    Jokinen MJ; Olkkola KT; Ahonen J; Neuvonen PJ
    Clin Pharmacol Ther; 2001 Oct; 70(4):344-50. PubMed ID: 11673750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
    Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
    Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.